NCT02996825

Who might be able to join this trial:

• Your cancer must be one of the following types that has come back, and must test positive for a protein called "folate receptor alpha" (FRα) on a special lab test: ovarian, primary peritoneal, or fallopian tube cancer (but not low-grade, clear cell, or sarcomatoid types); endometrial (uterine) cancer; or triple-negative breast cancer (TNBC) confirmed by specific lab testing
• You must have at least one tumor that can be measured on a scan, or — for ovarian/fallopian tube/peritoneal cancer only — a blood marker called CA-125 that is at least twice the normal level
• You must have already tried standard treatments that are known to help your cancer type, and those treatments must have stopped working or you were unable to tolerate them
• Your doctor expects you to live for more than 3 months
• Your blood counts must be healthy enough (checked within 14 days of joining): enough white blood cells, platelets, and your liver and kidney function must be within acceptable ranges
• If you could become pregnant, you must have a negative pregnancy test before starting and agree to use reliable birth control during the study and for 3 months after your last dose
• You must agree to allow the trial team to study your existing stored tumor tissue
• You must be willing and able to sign a consent form agreeing to take part
• Any side effects from your most recent chemotherapy must have mostly cleared up (rated grade 1 or lower), except for hair loss
• For TNBC patients (Cohort A): You must have had no more than 4 previous chemotherapy regimens, and must have already tried (or been unable to tolerate) certain standard chemotherapy drugs such as anthracyclines, taxanes, capecitabine, or eribulin
• For endometrial cancer patients (Cohort B): You must have had no more than 2 previous chemotherapy regimens, and must have already tried (or been unable to tolerate) platinum-based drugs, taxanes, or liposomal doxorubicin
• For ovarian/fallopian tube/peritoneal cancer patients (Cohort C): You must have had no more than 4 previous chemotherapy regimens, your cancer must no longer be responding to platinum-based chemotherapy, and you must have already tried (or been unable to tolerate) taxanes or liposomal doxorubicin; you must also agree to have a tumor biopsy 48–72 hours after your first treatment dose, if it is safe to do so

Who may not be able to join:

• You have previously been treated with gemcitabine (one of the drugs used in this trial)
• You have previously been treated with any experimental drug that targets the folate receptor
• You have received chemotherapy, biological therapy, or other cancer treatments within the past 3 weeks (or 6 weeks for certain specific drugs) before starting the trial
• You have received radiation therapy within the past 14 days before starting the trial
• You have had another cancer in the past 3 years, unless it was a type of skin cancer (basal or squamous cell), a very early-stage bladder cancer, or a cancer confined to one area that was fully treated
• You have cancer that has spread to the brain
• You have a serious active infection, including known hepatitis B or C, HIV, shingles, cytomegalovirus, or any other infection currently requiring intravenous (IV) antibiotics
• You have significant heart problems (such as heart failure, irregular heartbeat, or unstable chest pain), or have had a stroke within the past 6 months, or have a mental health or personal situation that would make it difficult to follow the trial requirements; an abnormal heart rhythm measurement (QT interval) above certain levels also applies (confirm with trial site)
• You have a history of a lung condition called interstitial pneumonitis (scarring or inflammation of the lungs)
• You have a history of serious liver scarring (cirrhosis)
• You have nerve damage in your hands or feet worse than mild (greater than grade 1 peripheral neuropathy)
• You have an active or ongoing eye condition, including Sjögren's syndrome, certain corneal diseases, a history of corneal transplant, active eye herpes, wet macular degeneration needing injections, diab